← Back to Search

Other

BMS-986207 for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization to time of death, 2.3 months
Awards & highlights

Study Summary

This trial will test a new cancer treatment involving a combination of drugs. The goal is to see if it is safe and effective for people with stage IV non-small cell lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization to time of death, 2.3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization to time of death, 2.3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival by BICR
Secondary outcome measures
Duration of Response (DOR) by Investigator
Number of Participants Who Had AEs, SAEs, AEs Leading to Discontinuation and Deaths.
Overall Response Rate (ORR) by BICR
+3 more

Side effects data

From 2022 Phase 2 trial • 1 Patients • NCT05005273
100%
Hypoalbuminaemia
100%
Hypokalaemia
100%
Blood lactate dehydrogenase increased
100%
Sepsis
100%
Nausea
100%
Blood alkaline phosphatase increased
100%
Hyponatraemia
100%
Cardiac arrest
100%
Eczema
100%
Bronchitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Nivolumab 360 mg + Ipilimumab 1 mg/kg + BMS-986207 600 mg
Nivolumab 360 mg + Ipilimumab 1 mg/kg + Placebo

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment3 Interventions
Group II: Arm AExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~4750
Ipilimumab
2014
Completed Phase 3
~2610
BMS-986207
2022
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,831 Total Patients Enrolled
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top